Our study investigates a novel combination therapy that capitalizes on the synergistic effects of Newcastle disease virus (NDV), Everolimus (EVE), and Beclin-1 (BEC) in treating human papillomavirus-associated cervical cancers in the mouse models. The gene discussed is BECN1; the disease is cervical carcinoma.